UK markets open in 2 hours 8 minutes

Bone Therapeutics SA (BNZPF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.20000.0000 (0.00%)
At close: 11:30AM EDT

Bone Therapeutics SA

Rue Granbonpré 11 - Bâtiment H
Mont-Saint-Guibert 1435
32 49 309 73 66

Full-time employees20

Key executives

NameTitlePayExercisedYear born
Dr. Miguel Forte M.D., Ph.D.CEO, MD & Exec. Director347.75kN/A1960
Dr. Anne-Sophie Lebrun Ph.D.Chief Operations OfficerN/AN/A1983
Dr. Anthony Ting Ph.D.Chief Scientific OfficerN/AN/A1963
Gunther De BackerHead of Corp. Communications & Investor RelationsN/AN/AN/A
Valerie ChapelleInterim HR DirectorN/AN/AN/A
Dr. Stefanos Theoharis Ph.D.Chief Bus. OfficerN/AN/A1976
Dr. Anne Leselbaum M.D.Chief Medical OfficerN/AN/A1966
Mr. Ching Man ChoiBus. Devel. Mang.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. Its products include ALLOB, an allogeneic cell therapy product, which is in Phase I/IIa clinical trial for the treatment of delayed-union fractures and lumbar spinal fusion; and JTA-004, an intra-articular injectable that is in phase III clinical trial to treat osteoarthritic pain in the knee. Bone Therapeutics SA was incorporated in 2006 and is based in Mont-Saint-Guibert, Belgium.

Corporate governance

Bone Therapeutics SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.